

# Syngene

Ref: Syn/CS/SE/Reg 30/2022-23/May/07

Syngene International Limited  
Biocon Park SEZ, Bommasandra IV Phase,  
Jigani Link Road, Bangalore 560 099,  
India.  
T +91 80 2808 2808  
F +91 80 4014 3150 / 2852 3423  
CIN No. L85110KA1993PLC014937  
[www.syngeneintl.com](http://www.syngeneintl.com)

May 11, 2022

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001 <b>Scrip Code: 539268</b>	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051 <b>Scrip Symbol: SYNGENE</b>
----------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

**Subject: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").**


Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions and balances for the half year ended March 31, 2022.

The above information will also be available on the website of the Company at [www.syngeneintl.com](http://www.syngeneintl.com).


Request you to kindly take this intimation on record and acknowledge.

Thanking You,

Yours faithfully,  
For **SYNGENE INTERNATIONAL LIMITED**



Priyadarshini Mahapatra  
Company Secretary and Compliance Officer



Disclosure of Related Party Transactions for the half-year ended March 31, 2022.

(Rs in millions)

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

S. No	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the counterparty	Type of related party transaction	Value of the related party transaction as approved by the audit committee for FY 2021-22	Value of transaction during the reporting period (i.e 6 months ending 31.03.2022)	In case monies are due to either party as a result of the transaction	Opening balance	Closing balance	In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances & investments	Details of the loans, inter-corporate deposits, advances or investments	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
1	Syngene International Limited	Kiran Mazumdar Shaw	Non-Executive Chairperson	Sitting fees and commission	Not applicable			3.77							
2	Syngene International Limited	Jonathan Hunt	Managing Director and Chief Executive Officer	Remuneration	Not applicable			48.4							
3	Syngene International Limited	Professor Catherine Rosenberg	Non-Executive Director	Sitting fees and commission	Not applicable			3.5							
4	Syngene International Limited	Paul Blackburn	Independent Director	Sitting fees and commission	Not applicable			3.63							
5	Syngene International Limited	Dr.Vijay Kuchroo	Independent Director	Sitting fees and commission	Not applicable			3.19							
6	Syngene International Limited	Vinita Ball	Independent Director	Sitting fees and commission	Not applicable			3.54							
7	Syngene International Limited	Dr.Carl Decicco	Non-Executive Director	Sitting fees and commission	Not applicable			2.59							
8	Syngene International Limited	Sharmila Karve	Independent Director	Sitting fees and commission	Not applicable			3.4							
9	Syngene International Limited	Dr.Kush Parmar	Independent Director	Sitting fees and commission	Not applicable			2.5							
10	Syngene International Limited	Sibaji Biswas	Chief Financial Officer	Remuneration	Not applicable			21.72							
11	Syngene International Limited	Priyadarshini Mahapatra	Company Secretary	Remuneration	Not applicable			4.19							
12	Syngene International Limited	Biocon Limited	Holding Company	Rent, Power and facility charges Purchase of goods Sales of services Other expenses	900	389.66	60	24.12							
13	Syngene International Limited	Biocon Biologics Limited	Fellow subsidiary	Purchase of goods Sales of services Other expenses Leases Receipt of services	855	334.83	99.8	114.99							
14	Syngene International Limited	Biocon SDN BHD	Fellow subsidiary	Sales of services	52	34.42	16	34.96							
15	Syngene International Limited	Biocon Biologics UK Limited	Fellow subsidiary	Sales of services	100	45.04	9.6	34.97							
16	Syngene International Limited	Biofusion Therapeutics Limited	Fellow subsidiary	Leases	50	9.52	10	19.03							
17	Syngene International Limited	Biocon Pharma Limited	Fellow subsidiary	Purchase of goods Sales of services	250	35.9	0.5	35.34							
18	Syngene International Limited	Bicara Therapeutics Inc	Associate of Holding Company	Sales of services	400	231.96	335.42	354.5							
19	Syngene International Limited	Biocon Foundation	Trust in which a director is a trustee	Contribution towards CSR	60	24.5	0	0							
20	Syngene International Limited	Naroyana Hrudayalaya Limited	Enterprise in which a director of the Company is a member of board of directors	Purchase of goods Sales of services	20	3.46	0.87	0.26							
21	Syngene International Limited	Jeeves	Enterprise in which relative to a director of the Company is proprietor	Others	8	1.79	0	0							
22	Syngene International Limited	Immuneel Therapeutics Private Limited	Enterprise in which a director of the Company is a member of board of directors	Sales of services	10	0.04	6	0							